The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CYCC | -99.12% | -99.99% | -83.12% | -100% |
| S&P | +16.23% | +94.45% | +14.22% | +421% |
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
The pharmaceutical company hopes to reap gross proceeds of around $20 million from the offering.
These five stocks bucked last week's uptrend by taking a dive.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.00M | -150.0% |
| Gross Margin | 90.00% | 0.0% |
| Market Cap | $7.85M | 267.5% |
| Net Income | -$1.32M | 59.5% |
| EBITDA | -$1.32M | 70.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.28M | -28.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.01M | 100.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -101.76% | 40.4% |
| Return On Invested Capital | -633.01% | 115.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.06M | 65.8% |
| Operating Free Cash Flow | -$1.06M | 65.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.20 | -1.53 | 18.91 | 2.16 | -323.44% |
| Price to Sales | 28.79 | 77.47 | 4134.88 | 784.77 | 2046.80% |
| Price to Tangible Book Value | -527.18 | -200.22 | -273.06 | 20.97 | -109.03% |
| Enterprise Value to EBITDA | 0.39 | -0.11 | -10.81 | -2.72 | -493.28% |
| Return on Equity | -329.4% | -807.4% | -1949.8% | -276.7% | -12.65% |
| Total Debt | $0.00M | $0.00M | $0.01M | $0.01M | 100.00% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
